Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
NCT02657486Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of infigratinib in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Tumor Response at 7 weeks. Started Jan 2016; status: completed.
02
Drugs
infigratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02657486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657486.